Last updated on April 2018

The Role of Dysmyelination in Cognitive Impairment of Psychotic Spectrum Disorders


Brief description of study

This is a single center study that uses both between-group comparisons and correlational analyses to establish biomarkers of dysmyelination and cognitive impairment in Psychotic Spectrum Disorders using imaging and neuropsychological assays.The study will provide non-invasive biomarkers of cognitive dysfunction in Psychotic Spectrum Disorder.

Clinical Study Identifier: NCT03166098

Contact Investigators or Research Sites near you

Start Over

Mariana Lazar, MD

New York University School of Medicine
New York, NY United States
  Connect »